These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36693762)

  • 1. Future directions for medicinal chemistry in the field of oligonucleotide therapeutics.
    Hall J
    RNA; 2023 Apr; 29(4):423-433. PubMed ID: 36693762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Medicinal Chemistry of Therapeutic Oligonucleotides.
    Wan WB; Seth PP
    J Med Chem; 2016 Nov; 59(21):9645-9667. PubMed ID: 27434100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic RNA-silencing oligonucleotides in metabolic diseases.
    Goga A; Stoffel M
    Nat Rev Drug Discov; 2022 Jun; 21(6):417-439. PubMed ID: 35210608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress toward oligonucleotide therapeutics: pharmacodynamic properties.
    Crooke ST
    FASEB J; 1993 Apr; 7(6):533-9. PubMed ID: 7682523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule oligonucleotides as smart modality for antiviral therapy: a medicinal chemistry perspective.
    Kar SS; Dhar AK; Palei NN; Bhatt S
    Future Med Chem; 2023 Jun; 15(12):1091-1110. PubMed ID: 37584172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal Chemistry of Oligonucleotide Drugs - Milestones of the Past and Visions for the Future.
    Hall J; Ashkinadze A; Becker JP; Laski A; Manz EM; Moravčík Š; Sjöström S; Vincent M
    Chimia (Aarau); 2022 May; 76(5):466-473. PubMed ID: 38069719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oligonucleotide therapeutics - an emerging novel class of compounds].
    Wacheck V
    Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents.
    Baumann V; Winkler J
    Future Med Chem; 2014; 6(17):1967-84. PubMed ID: 25495987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics.
    Scharner J; Aznarez I
    Mol Ther; 2021 Feb; 29(2):540-554. PubMed ID: 33359792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
    Taniguchi H; Suzuki Y; Imai K; Adachi Y
    Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
    Jing X; Arya V; Reynolds KS; Rogers H
    Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The delivery of therapeutic oligonucleotides.
    Juliano RL
    Nucleic Acids Res; 2016 Aug; 44(14):6518-48. PubMed ID: 27084936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligonucleotide therapeutics: chemistry, delivery and clinical progress.
    Sharma VK; Watts JK
    Future Med Chem; 2015; 7(16):2221-42. PubMed ID: 26510815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Clicking" Gene Therapeutics: A Successful Union of Chemistry and Biomedicine for New Solutions.
    Astakhova K; Ray R; Taskova M; Uhd J; Carstens A; Morris K
    Mol Pharm; 2018 Aug; 15(8):2892-2899. PubMed ID: 29300491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical techniques currently used in the pharmaceutical industry for the quality control of RNA-based therapeutics and ongoing developments.
    Demelenne A; Servais AC; Crommen J; Fillet M
    J Chromatogr A; 2021 Aug; 1651():462283. PubMed ID: 34107400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustainable practices in medicinal chemistry: current state and future directions.
    Bryan MC; Dillon B; Hamann LG; Hughes GJ; Kopach ME; Peterson EA; Pourashraf M; Raheem I; Richardson P; Richter D; Sneddon HF
    J Med Chem; 2013 Aug; 56(15):6007-21. PubMed ID: 23586692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.
    Shen X; Corey DR
    Nucleic Acids Res; 2018 Feb; 46(4):1584-1600. PubMed ID: 29240946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technical Considerations for Use of Oligonucleotide Solution API.
    Muslehiddinoglu J; Simler R; Hill ML; Mueller C; Amery JHA; Dixon L; Watson A; Storch K; Gazziola C; Gielen F; Lange SA; Prail JD; Nesta DP
    Nucleic Acid Ther; 2020 Aug; 30(4):189-197. PubMed ID: 32379529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in the chemistry, analysis and control for the manufacture of therapeutic-grade synthetic oligonucleotides.
    Sinha ND; Michaud DP
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):807-18. PubMed ID: 17987530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.